Guoliang Lv and Lifu Zhao contributed equally to this study.
Bioartificial liver system based on choanoid fluidized bed bioreactor improve the survival time of fulminant hepatic failure pigs†
Article first published online: 14 APR 2011
Copyright © 2011 Wiley Periodicals, Inc.
Biotechnology and Bioengineering
Volume 108, Issue 9, pages 2229–2236, September 2011
How to Cite
Lv, G., Zhao, L., Zhang, A., Du, W., Chen, Y., Yu, C., Pan, X., Zhang, Y., Song, T., Xu, J., Chen, Y. and Li, L. (2011), Bioartificial liver system based on choanoid fluidized bed bioreactor improve the survival time of fulminant hepatic failure pigs. Biotechnol. Bioeng., 108: 2229–2236. doi: 10.1002/bit.23150
- Issue published online: 18 JUL 2011
- Article first published online: 14 APR 2011
- Accepted manuscript online: 31 MAR 2011 07:59AM EST
- Manuscript Accepted: 21 MAR 2011
- Manuscript Revised: 23 FEB 2011
- Manuscript Received: 14 DEC 2010
- National S&T Major Project for Infectious Disease Control of China. Grant Number: 2008ZX10002-005
- National High Technology Research and Development Program of China. Grant Number: 2006AA02A140
- National Natural Science Foundation of China. Grant Number: 30630023
- bioartificial liver;
- fulminant hepatic failure;
- fluidized bed bioreactor
Bioartificial liver (BAL) support system has been proposed as potential treatment method for end-stage liver diseases. We described an improved BAL system based on a choanoid fluidized bed bioreactor containing alginate–chitosan encapsulated primary porcine hepatocytes. The feasibility, safety, and efficiency of this device were estimated using an allogeneic fulminant hepatic failure (FHF) model. FHF was induced with intravenous administration of D-galactosamine. Thirty FHF pigs were divided into three groups: (1) an FHF group which was only given intensive care; (2) a sham BAL group which was treated with the BAL system with empty encapsulation, and (3) a BAL group which was treated with the BAL system containing encapsulated freshly isolated primary porcine hepatocytes. The survival times and biochemical parameters of these animals were measured, and properties of the encapsulations and hepatocytes before and after perfusion were also evaluated. Compared to the two control groups, the BAL-treated group had prolonged the survival time and decreased the blood lactate levels, blood glucose, and amino acids remained stable. No obvious ruptured beads or statistical decline in viability or function of encapsulated hepatocytes were observed. This new fluidized bed BAL system is safe and efficient. It may represent a feasible alternative in the treatment of liver failure. Biotechnol. Bioeng. 2011;108:2229–2236. © 2011 Wiley Periodicals, Inc.